Recent Updates
Recently added Catalysts

Metastatic Hepatocellular Carcinoma: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$1.5Buniverse median $1.20B
Allocated capital$495M$1.5B competing
Phase 3 or filed00 mid, 1 early
Pure plays0this indication only
Capital rank199/299crowding rank 205

Metastatic Hepatocellular Carcinoma is uncontested. Tyra Bioscience (TYRA) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with TYRA-430 in phase 1.

There is no public comparable to price it against. TYRA spreads its $1.5B market cap across 3 indications, so $495M of it is allocated here.

Nothing here has reached Phase 3: 0 programmes in mid stage and 1 in early stage, so the field is still several years from a first approval.

$495M of allocated capital sits in Metastatic Hepatocellular Carcinoma, ranking it 199th of 299 indications by the money committed to it.

Companies developing drugs for Metastatic Hepatocellular Carcinoma 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
TYRATyra BioscienceTYRA-430Phase 11$1.5BNo3 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Metastatic Hepatocellular Carcinoma counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Metastatic Hepatocellular Carcinoma has one competitor and a median of $1.5B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

HER2 Expressing/Amplified Solid Tumors1 company · $484M · median $1.9BUncontestedHormone-refractory Prostate Adenocarcinoma1 company · $484M · median $1.9BUncontestedHR+/HER2- Breast Cancer1 company · $469M · median $939MUncontestedTriple Negative Metastatic Breast Cancer1 company · $448M · median $1.8BUncontestedEwing Sarcoma1 company · $448M · median $1.8BUncontestedChondrosarcoma1 company · $448M · median $1.8BUncontestedMultiple Myeloma3 companies · $421M · median $460MOrphan cornerMyelodysplastic Syndromes2 companies · $572M · median $1.5BConcentrated bet

Metastatic Hepatocellular Carcinoma pipeline questions

Which biotech companies are developing drugs for Metastatic Hepatocellular Carcinoma?

Tyra Bioscience (TYRA, TYRA-430, Phase 1). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Metastatic Hepatocellular Carcinoma.

How advanced is the Metastatic Hepatocellular Carcinoma pipeline?

Of the 1 clinical-stage programme in Metastatic Hepatocellular Carcinoma, 0 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Is anyone else developing a drug for Metastatic Hepatocellular Carcinoma?

No. TYRA is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Metastatic Hepatocellular Carcinoma, which is why the indication is classified as uncontested.

When is the next Metastatic Hepatocellular Carcinoma catalyst?

The next dated catalyst in Metastatic Hepatocellular Carcinoma is TYRA on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map